Related Experiment Video

Updated: Aug 13, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma

Nobuyasu Hayashi1, Shoji Nakamori, Nobuaki Hiraoka

  • 1Department of Surgery and Clinical Oncology Graduate School of Medicine, Osaka University, Suita City, Osaka 565-0871, Japan.

International Journal of Oncology
|December 5, 2003
PubMed

Insights

Anaplastic thyroid carcinoma (ATC) is aggressive. PPARgamma ligands show therapeutic potential by inhibiting ATC cell proliferation and invasion, suggesting PPARgamma as a novel therapeutic target for ATC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Anaplastic thyroid carcinoma (ATC) is a highly aggressive thyroid cancer.
  • ATC exhibits resistance to conventional treatments due to rapid growth and invasiveness.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) influences cell proliferation, differentiation, and apoptosis.

Purpose of the Study:

  • To investigate the therapeutic potential of PPARgamma ligands against anaplastic thyroid carcinoma cells in vitro.
  • To examine PPARgamma gene and protein expression in human ATC cell lines.
  • To assess the impact of PPARgamma ligands on ATC cell proliferation, differentiation, apoptosis, and invasion.

Main Methods:

  • Analysis of PPARgamma gene and protein expression in five human ATC cell lines.
  • Treatment of ATC cell lines with PPARgamma ligands (Thiazolidinedione, Prostaglandin J2, RS1303).
  • Evaluation of cell proliferation, differentiation, apoptosis, and invasion following ligand treatment.

Main Results:

  • ATC cell lines demonstrated higher PPARgamma expression compared to papillary thyroid carcinoma.
  • PPARgamma ligands inhibited ATC cell proliferation and invasion in a dose-dependent manner.
  • Inhibition was linked to induced apoptosis rather than differentiation, with greater effects in cell lines expressing higher PPARgamma levels.

Conclusions:

  • PPARgamma ligands modulate the malignant potential of ATC cells by affecting growth and invasion.
  • PPARgamma represents a potential novel molecular target for the treatment of human anaplastic thyroid carcinoma.
  • Targeting PPARgamma may offer a new therapeutic strategy for aggressive thyroid cancers.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...